Folate and depression

Psychotherapy and Psychosomatics

Volumn 72, Issue 2, 2003, Pages 59-60

  Bjelland, Ingvar ^a   Ueland, Per M ^a   Vollset, Stein Emil ^a  

^a UNIVERSITY OF BERGEN   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); AMINE; ANTIDEPRESSANT AGENT; COBALAMIN; FOLIC ACID; HOMOCYSTEINE; LIPID; METHYLMALONIC ACID; N METHYL DEXTRO ASPARTATE GLUTAMATE RECEPTOR; RECEPTOR; S ADENOSYLMETHIONINE; UNCLASSIFIED DRUG;

ANOREXIA; CENTRAL NERVOUS SYSTEM; CLINICAL TRIAL; DEPRESSION; EDITORIAL; ENZYME POLYMORPHISM; FOLIC ACID DEFICIENCY; HUMAN; MENTAL DISEASE; METHYLATION; PRIORITY JOURNAL; PROTEIN SYNTHESIS;

DEPRESSIVE DISORDER; FOLIC ACID DEFICIENCY; HUMANS; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); OXIDOREDUCTASES ACTING ON CH-NH GROUP DONORS; POLYMORPHISM, GENETIC;

EID: 0037217558     PISSN: 00333190     EISSN: None     Source Type: Journal    
DOI: 10.1159/000068693     Document Type: Editorial

References (20)

1. Herbert V: Experimental nutritional folate deficiency in man. Trans Assoc Am Physicians 1961;75:307-320.
2. Alpert JE, Mischoulon D, Nierenberg AA, Fava M: Nutrition and depression: Focus on folate. Nutrition 2000;16:544-436.
3. 12 deficiency and depression in physically disabled older women: Epidemiologic evidence from the Women's Health and Aging Study. Am J Psychiatry 2000;157:715-721.
4. 12, C and folate concentrations in the New Mexico elder health survey: Correlations with cognitive and affective functions. J Am Coll Nutr 2000;19:68-76.
5. Morris MS, Fava M, Jacques PF, Selhub J, Rosenberg IH: Depression and folate status in the US population. Psychother Psychosom 2003;72:80-87.
6. Van Praag H: Neurotransmitters and CNS disease: Depression. Lancet 1982;ii:1259-1283.
7. Bottiglieri T, Hyland K, Reynolds EH: The clinical potential of ademetionine (S-adenosylmethionine) in neurological disorders. Drugs 1994;48:137-152.
8. Spillmann M, Fava M:S-Adenosylmethionine (ademetionine) in psychiatric disorders. Historical perspectives and current status. CNS Drugs 1996;6:416-425.
9. Bottiglieri T, Laundy M, Crellin R, Toone BK, Carney MW, Reynolds EH: Homocysteine, folate, methylation, and monoamine metabolism in depression. J Neurol Neurosurg Psychiatry 2000;69:228-232.
10. 12, and homocysteine in major depressive disorder. Am J Psychiatry 1997;154:426-428.
11. Reynolds EH, Preece JM, Bailey J, Coppen A: Folate deficiency in depressive illness. Br J Psychiatry 1970;117:287-292.
12. Ueland PM, Hustad S, Schneede J, Refsum H, Vollset SE: Biological and clinical implications of the MTHFR C677T polymorphism. Trends Pharmacol Sci 2001;22:195-201.
13. Kunugi H, Fukuda R, Hattori M, Kato T, Tatsumi M, Sakai T, Hirose T, Nanko S: C677T polymorphism in methylenetetrahydrofolate reductase gene and psychoses. Mol Psychiatry 1998;3:435-437.
14. Arinami T, Yamada N, Yamakawa-Kobayashi K, Hamaguchi H, Toru M: Methylenetetrahydrofolate reductase variant and schizophrenia/depression. Am J Med Genet 1997;74:526-528.
15. Passeri M, Cucinotta D, Abate G, Senin U, Ventura A, Stramba Badiale M, Diana R, La Greca P, Le Grazie C: Oral 5′-methyltetrahydrofolic acid in senile organic mental disorders with depression: Results of a double-blind multicenter study. Aging (Milano) 1993;5:63-71.
16. Coppen A, Bailey J: Enhancement of the anti-depressant action of fluoxetine by folic acid: A randomised, placebo-controlled trial. J Affect Disord 2000;60:121-130.
17. Godfrey PS, Toone BK, Carney MW, Flynn TG, Bottiglieri T, Laundy M, Chanarin I, Reynolds EH: Enhancement of recovery from psychiatric illness by methylfolate. Lancet 1990;336:392-395.
18. Coppen A, Chaudhry S, Swade C: Folic acid enhances lithium prophylaxis. J Affect Disord 1986;10:9-13.
19. Reynolds EH: Benefits and risks of folic acid to the nervous system. J Neurol Neurosurg Psychiatry 2002;72:567-571.
20. Jacques PF, Selhub J, Bostom AG, Wilson PW, Rosenberg IH: The effect of folic acid fortification on plasma folate and total homocysteine concentrations. N Engl J Med 1999;340:1449-1454.